Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0086
-0.0001 (-1.15%)
Streaming Delayed Price
Updated: 12:34 PM EST, Jan 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revive Therapeutics Ltd
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 19, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
↗
January 17, 2023
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.
Via
Benzinga
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
↗
January 12, 2023
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.<
Via
Benzinga
Revive Therapeutics Ltd. Closes $4.3 Million Offering
January 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
January 09, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 05, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
December 22, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
↗
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
↗
December 16, 2022
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).
Via
Benzinga
Revive Therapeutics Ltd. Expands Life Offering to Quebec
December 15, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics To Raise Up To $5M Via Private Placement
↗
December 01, 2022
REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;.
Via
Benzinga
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
November 30, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From November 30, 2022
↗
November 30, 2022
Via
Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
November 29, 2022
Via
Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
↗
November 28, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022
↗
November 25, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
↗
November 24, 2022
Via
Benzinga
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 24, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From November 23, 2022
↗
November 23, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
↗
November 22, 2022
Via
Benzinga
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 22, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From November 21, 2022
↗
November 21, 2022
Via
Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today
↗
November 18, 2022
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
↗
November 17, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022
↗
November 16, 2022
Via
Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
November 15, 2022
Via
Benzinga
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
↗
November 10, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05
Via
Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
↗
November 09, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS:
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 8, 2022
↗
November 08, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
